(BUSINESS WIRE) -- The Institute of Food Technologists (IFT), a nonprofit scientific organization committed to advancing the science of food and its application across the global food system, and the Seeding The Future Foundation are proud to announce the return of the annual Seeding The Future Global Food System Challenge. The Challenges invites scientists, engineers, innovators, entrepreneurs, and multidisciplinary teams from non-governmental organizations (NGOs), non-profits, social enterprises, universities, research institutions as well as small and emerging startups to submit their game-changing innovations that will help transform the global food system.
Now in its third year, the Challenge will once again award $1 million in grants and prizes via Seed Grants ($25,000 each), Growth Grants ($100,000 each), and Seeding The Future Grand Prizes ($250,000 each). Last year’s Growth Grant and Grand Prize winners included:
Commercializing black soldier fly larva
...
Read more »
|
Inaugural report developed in-line with Global Reporting Initiative standards and creates a framework for achievement including strategic alignment with governing standards
Energy Vault details its sustainability strategy, incorporating awareness and alignment with the United Nations Sustainable Development Goals
(BUSINESS WIRE) -- Energy Vault Holdings, Inc. (NYSE: NRGV) (“Energy Vault” or the “Company”), a leader in sustainable grid-scale energy storage solutions, announced today the publication of its inaugural
...
Read more »
|
INGELHEIM, Germany & SINGAPORE - Tuesday, 09. May 2023
(BUSINESS WIRE) -- Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas. The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte. Ltd. (Enleofen), with a goal to improve patient outcomes.
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissue
...
Read more »
|
NEUCHATEL, Switzerland - Monday, 08. May 2023
(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) today announced that Cambridge University Hospitals NHS Foundation Trust, U.K. is adopting the Masimo W1™ advanced health tracking watch for use in its telehealth and telemedicine programs. Masimo W1, which offers accurate, continuous measurements of key physiological parameters, is available in the UK as a medical device that integrates with the Masimo SafetyNet® remote patient management platform.
Joe Kiani, Founder and CEO of Masimo, said, “Masimo W1 represents not only the future of personal health but is playing a vital role in the expansion of remote healthcare. Built on our decades of expertise developing breakthrough noninvasive medical monitoring technologies, Masimo W1 is designed to aid valued hospital partners like Cambridge in accelerating their virtual hospital and telehealth programs – ultimately helping to improve patient outcomes while reducin
...
Read more »
|
ACCRA, Ghana - Tuesday, 09. May 2023
(BUSINESS WIRE)--Today, AZA Finance released a brief unveiling critical insights in the Ghanaian fintech landscape, emphasising the crucial roles of banks, regulators, and fintech in driving global investment into this thriving market.
Authored by Elizabeth Rossiello, CEO and founder of AZA Finance, and Nana Yaw Owusu Banahene, Country Manager (Ghana) at AZA Finance, the report provides insight into Ghana's regulatory environment, key statistics, and a promising outlook for businesses seeking to establish a presence in this burgeoning market.
The report reveals Ghana's digital transformation, fueled by tech-savvy regulators, robust banking infrastructure, and the responsible expansion of fintech, as key factors contributing to its attractiveness for international fintech, multinational corporations, and investors.
Notable highlights from the report include:
Increasing fund flows from the United King
...
Read more »
|
MARRAKECH, Morocco - Tuesday, 09. May 2023
#AviramAwards
(BUSINESS WIRE)--Five trailblazing entrepreneurs from across North Africa and the Middle East have been selected as finalists for the 2023 Aviram Awards competition hosted by the Aviram Foundation and Forbes in Marrakech on May 16th, 2023. President Bill Clinton will also join the event as a headline speaker.
Each year the Aviram Awards aims to identify, mentor and support ventures in the region which have the potential to drive significant social and environmental change through innovation and technology. This year’s finalists were selected by impressing the international judging panel with their proposals for ground-breaking technology that will change the world for the better. The finalists are:
Youssef Bouyakhf, CEO and cofounder of Deepecho (Morocco) which uses AI to assist minimally trained ultrasound technicians in advanced video diagnosis. The product detects birth defects and allows
...
Read more »
|
SKILLMAN, N.J. - Tuesday, 09. May 2023 AETOSWire Print
(BUSINESS WIRE) -- Kenvue Inc. (NYSE: KVUE) (“Kenvue”) the world’s largest pure-play consumer health company by revenue, today announced the closing of its initial public offering (“IPO”) of 198,734,444 shares of its common stock at a price to the public of $22.00 per share, including the underwriters’ full exercise of their option to purchase 25,921,884 shares to cover over-allotments. Shares of Kenvue’s common stock began trading on the New York Stock Exchange under the symbol “KVUE” on May 4, 2023.
As of the closing of the IPO, Johnson & Johnson (NYSE: JNJ) owns approximately 89.6% of the total outstanding shares of Kenvue common stock. Johnson & Johnson has publicly stated that it has an intention to dispose of its majority stake in Kenvue common stock in 2023, subject to market conditions.
The net proceeds from the IPO will be paid t
...
Read more »
|
(BUSINESS WIRE)--Intelligent power management company Eaton today announced it is continuing to expand and evolve its European eMobility business design capabilities, technologies and operations to support global electrified vehicle manufacturers. These upgrades will support Eaton’s efforts in delivering electric vehicle solutions to passenger car, commercial vehicle and off-highway OEMs globally.
“The electrification of automotive and commercial vehicle markets requires new capabilities to meet the changing industry,” said Mark Schneider, president, eMobility, Eaton. “We are seeing increasing global demand for electrified vehicle solutions that are designed and produced in our European locations.”
Montrottier producing power electronics components for global EV manufacturers
Eaton’s eMobility business has invested in a state-of-the-art production facility for power electronics components in Montrottier, France. High-volume
...
Read more »
|
HONG KONG & SUZHOU, China & SHANGHAI
(BUSINESS WIRE) -- Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.
"Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, particularly in the field of brain metastasis by virtue of the high blood-brain bar
...
Read more »
|
|